Analyzing the Data for Entrectinib in ROS1 TKI-Naive Patients With NSCLC

Alexander Drilon, MD, clinical director, Early Drug Development Service, associate professor of thoracic oncology service, Memorial Sloan Kettering Cancer Center, discusses the data examining the role of entrectinib in patients with non-small cell lung cancer (NSCLC) who are ROS1 TKI-naive. Drilon notes that previous experience in this patient population does not show any response with entrectinib; therefore, this is important because it is not only a CNS-active agent, but it is also considered more of an early-generation ROS1 inhibitor. Looking at treatment naive patients with ROS1 fusion-positive lung cancers, this trial had more than 50 patients, all of which had a ROS1 fusion detected. Topline results in terms of activity showed the objective response rate was high at 77%, Drilon says. Majority of patients had disease regression with this agent and also experienced some deep and durable responses. For more resources and information regarding anticancer targeted therapies in lung cancer: https://www.targetedonc.com/resource-...